Literature DB >> 16410818

Proton beam therapy for iris melanoma: a review of 15 cases.

P Rundle1, A D Singh, I Rennie.   

Abstract

AIM: To report results of proton beam therapy for iris melanoma.
METHODS: A retrospective case series of 15 patients with nonresectable iris melanomas treated with proton beam therapy between August 1998 and August 2004. The main outcome measures were (1) local tumour control, (2) complications, and (3) eye retention.
RESULTS: Of the 15 cases, 11 patients showed documented growth (including two cases of local recurrence following iridocyclectomy) while a further three cases were biopsy-proven melanoma. One patient presented with a newly acquired vascular nodule of the iris associated with angle seeding and glaucoma. Tumour control at mean follow-up of 34 months was 93% (14 of 15 eyes). Common complications included glaucoma in 53% (five patients had glaucoma prior to irradiation), dry eye (27%) and cataract in three patients (20%). Eye retention was possible in 80% (12 cases).
CONCLUSION: Proton beam therapy is an effective treatment for cases of nonresectable iris melanoma. The major complications are cataract and glaucoma.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16410818     DOI: 10.1038/sj.eye.6702132

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


  10 in total

Review 1.  Don't it make my blue eyes brown: heterochromia and other abnormalities of the iris.

Authors:  I G Rennie
Journal:  Eye (Lond)       Date:  2011-10-07       Impact factor: 3.775

2.  Proton therapy of iris melanoma with 50 CGE : Influence of target volume on clinical outcome.

Authors:  Aline I Riechardt; Bettina Karle; Dino Cordini; Jens Heufelder; Volker Budach; Antonia M Joussen; Johannes Gollrad
Journal:  Strahlenther Onkol       Date:  2017-06-19       Impact factor: 3.621

3.  Multifocal iris melanoma treated with total anterior segment palladium-103 plaque radiation therapy.

Authors:  Vasileois Petousis; Paul T Finger; Tatyana Milman
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-12-14       Impact factor: 3.117

4.  Plaque radiotherapy treatment with ruthenium-106 for iris malignant melanoma.

Authors:  M Tsimpida; J Hungerford; A Arora; V Cohen
Journal:  Eye (Lond)       Date:  2011-09-23       Impact factor: 3.775

5.  Baerveldt implant for secondary glaucoma due to iris melanoma.

Authors:  Annelie N Tan; Juliette G M M Hoevenaars; Carroll A B Webers; Bertil Damato; Henny J M Beckers
Journal:  Clin Ophthalmol       Date:  2010-05-06

6.  Proton beam therapy for presumed and confirmed iris melanomas: a review of 36 cases.

Authors:  Ahmed Rahmi; Hamid Mammar; Juliette Thariat; Gaelle Angellier; Joel Herault; Pierre Chauvel; Laurent Kodjikian; Philippe Denis; Jean Daniel Grange
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-07-20       Impact factor: 3.117

Review 7.  Diffuse Iris Melanoma: Conservative Treatment with Proton Beam Therapy after Limbal Stem Cell Preservation or Enucleation?

Authors:  Alice Leblanc; Livia Lumbroso-Le Rouic; Laurence Desjardins; Rémi Dendale; Nathalie Cassoux
Journal:  Ocul Oncol Pathol       Date:  2019-03-20

8.  Iris melanoma relapsing sixteen years after proton-beam therapy: The importance of lifelong follow-up.

Authors:  Laetitia-Claire Msika; Laurence Desjardins; Vincent Cockenpot; Rémi Dendale; Olivier Berges; Khadija Aït Raïs; Gaëlle Pierron; Raymond L Barnhill; Nathalie Cassoux; Alexandre Matet
Journal:  Am J Ophthalmol Case Rep       Date:  2018-12-06

9.  Current molecular and clinical insights into uveal melanoma (Review).

Authors:  Matteo Fallico; Giuseppina Raciti; Antonio Longo; Michele Reibaldi; Vincenza Bonfiglio; Andrea Russo; Rosario Caltabiano; Giuseppe Gattuso; Luca Falzone; Teresio Avitabile
Journal:  Int J Oncol       Date:  2021-03-02       Impact factor: 5.650

10.  Proton beam radiation for iris melanoma: case series and review of literature.

Authors:  Jasmine Alexandra Hauzinger; Georgios Blatsios; Gertrud Haas; Claus Zehetner; Luisa Velez-Escola; Yvonne Nowosielski; Christof Seifarth; Teresa Rauchegger; Bernhard Haider; Nikolaos E Bechrakis
Journal:  BMJ Open Ophthalmol       Date:  2021-12-23
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.